drugset / Trial / NCT00052013

Treatment of Von Hippel-Lindau (VHL)-Related Hemangioblastoma With PTK787/ZK 222584

NCT00052013

Phase 2 Completed 11 enrolled Novartis Pharmaceuticals
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine whether PTK787/ZK 222584 is effective in treating hemangioblastoma of the brain and/or retina in patients with von Hippel-Lindau disease. The study will also assess safety and tolerability of PTK787/ZK 222584, and changes in markers of angiogenesis (new blood vessel growth).

Timeline

Start
2003-02
Primary completion
2006-06
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject vatalanib Small molecule Oral